DW4421-N2

**DW4421-N2** is a trial-specific drug-intervention identifier used by Daewon Pharmaceutical in a Phase 1 healthy-volunteer drug-drug interaction study of DW4421 with three nonsteroidal anti-inflammatory drugs. The public trial record lists DW4421-N2 separately from DW4421, DW4421-N1, and DW4421-N3; it does not publicly disclose the chemical identity, structure, dosage form, or mechanism of the substance designated DW4421-N2. Accordingly, DW4421-N2 should not be treated as a confirmed synonym of padoprazan, which is the active substance identified for DW4421. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343245))